Pasireotide (SOM230), Octreotide (Sandostatin)

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Acromegaly

Conditions

Acromegaly

Trial Timeline

Mar 1, 2004 → —

NCT ID

NCT00088582

About Pasireotide (SOM230), Octreotide (Sandostatin)

Pasireotide (SOM230), Octreotide (Sandostatin) is a phase 2 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT00088582. Target conditions include Acromegaly.

What happened to similar drugs?

16 of 20 similar drugs in Acromegaly were approved

Approved (16) Terminated (1) Active (4)

✅Sandostatin LAR + pegvisomant + cabergolineNovartisApproved

✅Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved

✅Sandostatin LARNovartisApproved

✅Sandostatin (Octreotide Acetate)NovartisApproved

✅Octreotide acetateNovartisApproved

✅Pasireotide LAR 60 mg + PegvisomantNovartisApproved

✅OctreotideNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00088582	Phase 2	Completed	Mar 1, 2004	—	Acromegaly

Competing Products

20 competing products in Acromegaly

See all competitors

Product	Company	Stage	Hype Score
Alesse	Novartis	Phase 2	31
ONO-5788 + ONO-5788 Placebo + Octreotide	Ono Pharmaceutical	Phase 1	21
ONO-5788 + [14C]-ONO-5788	Ono Pharmaceutical	Phase 1	29
Pasireotide LAR	Novartis	Phase 3	40
Octreotide acetate 30 mg suspension	Novartis	Phase 3	40
Pasireotide long acting release formulation	Novartis	Pre-clinical	26
Sandostatin LAR + pegvisomant + cabergoline	Novartis	Approved	43
Octreotide acetate and cabergoline/Octrotide and Somavert	Novartis	Approved	43
Sandostatin LAR	Novartis	Approved	43
Pasireotide + Octreotide	Novartis	Phase 3	40
Sandostatin (Octreotide Acetate)	Novartis	Approved	39
Octreotide acetate	Novartis	Approved	35
octreotide FluidCrystal® injection depot	Novartis	Phase 2	35
Octreotide LAR	Novartis	Phase 3	40
Octreotide LAR	Novartis	Phase 3	40
Pasireotide	Novartis	Phase 2	35
Pasireotide LAR 60 mg + Pegvisomant	Novartis	Approved	39
Octreotide	Novartis	Approved	43
Octreotide LAR 30 MG Injection	Novartis	Approved	43
Pasireotide LAR	Novartis	Phase 2	35